DOP2021000068A - Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos - Google Patents
Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estosInfo
- Publication number
- DOP2021000068A DOP2021000068A DO2021000068A DO2021000068A DOP2021000068A DO P2021000068 A DOP2021000068 A DO P2021000068A DO 2021000068 A DO2021000068 A DO 2021000068A DO 2021000068 A DO2021000068 A DO 2021000068A DO P2021000068 A DOP2021000068 A DO P2021000068A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pharmaceutical compositions
- sulfonamide derivatives
- pyridinyl sulfonamide
- pyridinyl
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere a nuevos derivados de piridinil sulfonamida de la Fórmula (I) (I), en donde R1, A y n son como se definieron en la descripción y en las reivindicaciones, a su uso como medicamentos, a métodos para su uso terapéutico y a composiciones farmacéuticas que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203196 | 2018-10-29 | ||
| PCT/EP2019/078992 WO2020089026A1 (en) | 2018-10-29 | 2019-10-24 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000068A true DOP2021000068A (es) | 2021-06-30 |
Family
ID=64082994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000068A DOP2021000068A (es) | 2018-10-29 | 2021-04-16 | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20210361637A1 (es) |
| EP (1) | EP3873600B9 (es) |
| JP (1) | JP7317109B2 (es) |
| KR (1) | KR20210084537A (es) |
| CN (1) | CN112955215B (es) |
| AU (1) | AU2019373306A1 (es) |
| BR (1) | BR112021004635A2 (es) |
| CA (1) | CA3112510A1 (es) |
| CL (1) | CL2021000839A1 (es) |
| CO (1) | CO2021005509A2 (es) |
| CR (1) | CR20210216A (es) |
| DK (1) | DK3873600T5 (es) |
| DO (1) | DOP2021000068A (es) |
| EA (1) | EA202191114A1 (es) |
| EC (1) | ECSP21030482A (es) |
| ES (1) | ES2967359T3 (es) |
| FI (1) | FI3873600T3 (es) |
| HR (1) | HRP20231608T1 (es) |
| HU (1) | HUE064995T2 (es) |
| IL (1) | IL282428A (es) |
| LT (1) | LT3873600T (es) |
| MA (1) | MA54051A (es) |
| MX (1) | MX2021004940A (es) |
| PE (1) | PE20211467A1 (es) |
| PL (1) | PL3873600T3 (es) |
| PT (1) | PT3873600T (es) |
| RS (1) | RS64963B1 (es) |
| SA (1) | SA521421755B1 (es) |
| SG (1) | SG11202102440SA (es) |
| SI (1) | SI3873600T1 (es) |
| WO (1) | WO2020089026A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210353608A1 (en) * | 2018-10-29 | 2021-11-18 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| CN114945366A (zh) | 2019-09-13 | 2022-08-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| CN114621243B (zh) * | 2020-12-14 | 2024-03-01 | 上海拓界生物医药科技有限公司 | 一种磺酰胺类衍生物及其用途 |
| CN114621190B (zh) * | 2020-12-14 | 2023-12-05 | 上海拓界生物医药科技有限公司 | 一种烯丙基胺类衍生物及其用途 |
| CN114621189B (zh) * | 2020-12-14 | 2024-01-02 | 上海拓界生物医药科技有限公司 | 一种内酰胺类衍生物及其用途 |
| WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2275527C (en) | 1996-12-19 | 2003-09-23 | Hoechst Marion Roussel, Inc. | Novel heterocyclic substituted pyrrolidine amide derivatives |
| US20100197908A1 (en) | 2006-12-11 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2844637T (pt) | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
| MA44965B1 (fr) * | 2016-05-12 | 2021-02-26 | Boehringer Ingelheim Int | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |
| WO2018027892A1 (en) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| US20210353608A1 (en) * | 2018-10-29 | 2021-11-18 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
-
2019
- 2019-10-24 RS RS20231203A patent/RS64963B1/sr unknown
- 2019-10-24 KR KR1020217015606A patent/KR20210084537A/ko unknown
- 2019-10-24 CN CN201980071238.4A patent/CN112955215B/zh active Active
- 2019-10-24 PL PL19794970.4T patent/PL3873600T3/pl unknown
- 2019-10-24 MA MA054051A patent/MA54051A/fr unknown
- 2019-10-24 CA CA3112510A patent/CA3112510A1/en active Pending
- 2019-10-24 WO PCT/EP2019/078992 patent/WO2020089026A1/en active Application Filing
- 2019-10-24 HU HUE19794970A patent/HUE064995T2/hu unknown
- 2019-10-24 HR HRP20231608TT patent/HRP20231608T1/hr unknown
- 2019-10-24 ES ES19794970T patent/ES2967359T3/es active Active
- 2019-10-24 AU AU2019373306A patent/AU2019373306A1/en active Pending
- 2019-10-24 US US17/285,918 patent/US20210361637A1/en active Pending
- 2019-10-24 CR CR20210216A patent/CR20210216A/es unknown
- 2019-10-24 SI SI201930672T patent/SI3873600T1/sl unknown
- 2019-10-24 EA EA202191114A patent/EA202191114A1/ru unknown
- 2019-10-24 DK DK19794970.4T patent/DK3873600T5/da active
- 2019-10-24 BR BR112021004635-6A patent/BR112021004635A2/pt unknown
- 2019-10-24 PE PE2021000602A patent/PE20211467A1/es unknown
- 2019-10-24 PT PT197949704T patent/PT3873600T/pt unknown
- 2019-10-24 SG SG11202102440SA patent/SG11202102440SA/en unknown
- 2019-10-24 FI FIEP19794970.4T patent/FI3873600T3/fi active
- 2019-10-24 LT LTEPPCT/EP2019/078992T patent/LT3873600T/lt unknown
- 2019-10-24 MX MX2021004940A patent/MX2021004940A/es unknown
- 2019-10-24 EP EP19794970.4A patent/EP3873600B9/en active Active
- 2019-10-24 JP JP2021523407A patent/JP7317109B2/ja active Active
-
2021
- 2021-04-05 CL CL2021000839A patent/CL2021000839A1/es unknown
- 2021-04-14 SA SA521421755A patent/SA521421755B1/ar unknown
- 2021-04-16 DO DO2021000068A patent/DOP2021000068A/es unknown
- 2021-04-19 IL IL282428A patent/IL282428A/en unknown
- 2021-04-27 CO CONC2021/0005509A patent/CO2021005509A2/es unknown
- 2021-04-28 EC ECSENADI202130482A patent/ECSP21030482A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005509A2 (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| NI201800132A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CO2021000043A2 (es) | Degradadores selectivos del receptor de estrógeno | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| CR20170564A (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY37274A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| CO2021000041A2 (es) | Degradadores selectivos del receptor de estrógeno | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| CO2020007044A2 (es) | Derivados de pirrol como inhibidores de acc | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35876A (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| CO2021004553A2 (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio | |
| NI202000028A (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. |